Why FIIs Are Shunning India: Sridhar Sivaram Explains
Sridhar Sivaram, Investment Director at Enam Holdings, explains why Foreign Institutional Investors (FIIs) are avoiding Indian equities despite a strong rally in other emerging markets.
Sridhar Sivaram, Investment Director at Enam Holdings, explains why Foreign Institutional Investors (FIIs) are avoiding Indian equities despite a strong rally in other emerging markets.
ICICI Securities maintains a ‘buy’ call on Havells India despite near-term softness due to weak air conditioner demand and BEE norms changes, citing long-term growth potential.
LIC CEO R Doraiswamy expresses confidence in meeting competition head-on after the 100% FDI approval in the insurance sector, expecting better tech adoption, transparency, and customer service.
SEBI’s recent crackdown on unauthorised market advices has brought to light the scale of the problem. Find out how these unregistered market educators are affecting Indian investors and what SEBI is doing to regulate them.
Nifty is likely to touch 30,000 in the coming years as the worst phase of earnings downgrades and macro pressures is behind India, setting the stage for a stronger performance over the next year.
India’s infrastructure capex is on the cusp of a major boost ahead of the upcoming Budget 2026, with JPMorgan predicting a 10-12% CAGR growth in the defence sector over the next 10 years.
The Indian stock market extended its decline for the third consecutive day, with Nifty and Sensex ending lower due to a sell-off in key sectors. Get the latest updates on the Indian stock market, including Nifty levels, Sensex movements, and major corporate actions affecting investor sentiment.
Vedanta Ltd.’s demerger plan has been approved by the National Company Law Tribunal, paving the way for the splitting of the metals-to-oil conglomerate into sector-specific entities.
Tesla’s recent rally to a record high has left its big tech peers behind, driven by investor excitement about its work with artificial intelligence and autonomous-driving development efforts.
Aurobindo Pharma’s Andhra Pradesh-based Unit-IV receives Form 483 with five observations from the USFDA. What does this mean for investors and the company’s future prospects?